Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Perrigo Fends Off Hostile Mylan Bid

by Rick Mullin
November 23, 2015 | A version of this story appeared in Volume 93, Issue 46

Perrigo shareholders have rejected a $26 billion takeover bid from Mylan. Joseph C. Papa, CEO of Perrigo, a manufacturer of store-branded generic drugs, says the offer “significantly undervalued our durable business model and industry-leading future growth prospects.” The demise of the deal signals the end to a run of merger moves among generic drug firms in 2015, including Teva Pharmaceutical Industries’ thwarted attempt to acquire Mylan this summer. Teva instead bought the generics business of Allergan in July. Allergan acquired the specialty pharmaceuticals business of Actavis in March.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.